Next Article in Journal
Therapeutic Hypothermia Improves Hind Limb Motor Outcome and Attenuates Oxidative Stress and Neuronal Damage in the Lumbar Spinal Cord Following Cardiac Arrest
Previous Article in Journal
Hydroxytyrosol Decreases LPS- and α-Synuclein-Induced Microglial Activation In Vitro
Open AccessArticle

Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy

by Ming-Wei Lin 1,2,†, Chi Chien Lin 3,†, Yi-Hung Chen 4,5, Han-Bin Yang 3,4 and Shih-Ya Hung 4,6,*
Department of Medical Research, E-Da Hospital/E-Da Cancer Hospital, I-Shou University, Kaohsiung 82445, Taiwan
Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
Department of Life Sciences, Institute of Biomedical Science, National Chung Hsing University, Taichung 40249, Taiwan
Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan
Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan
Division of Colorectal Surgery, China Medical University Hospital, Taichung 40447, Taiwan
Author to whom correspondence should be addressed.
The authors contributed equally to this work.
Antioxidants 2020, 9(1), 37;
Received: 18 November 2019 / Revised: 27 December 2019 / Accepted: 27 December 2019 / Published: 31 December 2019
Parkinson’s disease (PD) is a neurodegenerative disease, which is associated with mitochondrial dysfunction and abnormal protein accumulation. No treatment can stop or slow PD. Autophagy inhibits neuronal death by removing damaged mitochondria and abnormal protein aggregations. Celastrol is a triterpene with antioxidant and anti-inflammatory effects. Up until now, no reports have shown that celastrol improves PD motor symptoms. In this study, we used PD cell and mouse models to evaluate the therapeutic efficacy and mechanism of celastrol. In the substantia nigra, we found lower levels of autophagic activity in patients with sporadic PD as compared to healthy controls. In neurons, celastrol enhances autophagy, autophagosome biogenesis (Beclin 1↑, Ambra1↑, Vps34↑, Atg7↑, Atg12↑, and LC3-II↑), and mitophagy (PINK1↑, DJ-1↑, and LRRK2↓), and these might be associated with MPAK signaling pathways. In the PD cell model, celastrol reduces MPP+-induced dopaminergic neuronal death, mitochondrial membrane depolarization, and ATP reduction. In the PD mouse model, celastrol suppresses motor symptoms and neurodegeneration in the substantia nigra and striatum and enhances mitophagy (PINK1↑ and DJ-1↑) in the striatum. Using MPP+ to induce mitochondrial damage in neurons, we found celastrol controls mitochondrial quality by sequestering impaired mitochondria into autophagosomes for degradation. This is the first report to show that celastrol exerts neuroprotection in PD by activating mitophagy to degrade impaired mitochondria and further inhibit dopaminergic neuronal apoptosis. Celastrol may help to prevent and treat PD. View Full-Text
Keywords: autophagy; celastrol; dopaminergic neurons; mitophagy; Parkinson’s disease autophagy; celastrol; dopaminergic neurons; mitophagy; Parkinson’s disease
Show Figures

Graphical abstract

MDPI and ACS Style

Lin, M.-W.; Lin, C.C.; Chen, Y.-H.; Yang, H.-B.; Hung, S.-Y. Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy. Antioxidants 2020, 9, 37.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop